Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
69452-0350-11 69452-0350 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2022 In Use
69452-0350-92 69452-0350 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2022 In Use
70121-1569-07 70121-1569 Filgrastim RELEUKO 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1571-07 70121-1571 Filgrastim RELEUKO 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
68071-2661-00 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-01 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-02 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-03 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-05 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68083-0535-10 68083-0535 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous April 22, 2022 In Use
68001-0524-30 68001-0524 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
68001-0524-31 68001-0524 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
68001-0525-27 68001-0525 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
68001-0525-32 68001-0525 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 18, 2022 In Use
65219-0029-20 65219-0029 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical April 11, 2022 In Use
64380-0158-01 64380-0158 Megestrol Acetate Megestrol Acetate 20.0 mg/1 Hormonal Therapy Progestin Analog Oral April 11, 2022 In Use
49884-0867-01 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0867-05 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0867-15 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-01 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-05 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-15 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-01 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-05 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-15 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
68180-0390-09 68180-0390 IMATINIB IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 8, 2019 In Use
68180-0391-06 68180-0391 IMATINIB IMATINIB MESYLATE 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 8, 2019 In Use
70518-2914-00 70518-2914 Methylprednisolone Acetate Methylprednisolone Acetate 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intralesional, Intramuscular, Intrasynovial, Soft Tissue Oct. 21, 2020 In Use
45865-0598-10 45865-0598 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 3, 2015 In Use
45865-0598-30 45865-0598 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 3, 2015 In Use
45865-0638-21 45865-0638 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 11, 2015 In Use
62559-0920-14 62559-0920 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 16, 2020 In Use
62559-0920-51 62559-0920 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 16, 2020 In Use
71288-0143-02 71288-0143 Docetaxel anhydrous Docetaxel anhydrous 20.0 mg/2mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 24, 2018 In Use
00378-9040-05 00378-9040 Cysteamine bitartrate Cystagon 50.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral April 11, 2005 In Use
00378-9045-05 00378-9045 Cysteamine bitartrate Cystagon 150.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral April 11, 2005 In Use
57377-0060-01 57377-0060 Testosterone, USP and Anastrozole Testozole 4.0 mg/1, 60.0 mg/1 Hormonal Therapy Androgen/Aromatase Inhibitor Subcutaneous Jan. 1, 2021 In Use
65174-0880-00 65174-0880 Sodium Iodide I 131 HICON 1000.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral April 7, 2003 In Use
65174-0880-25 65174-0880 Sodium Iodide I 131 HICON 1000.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral April 7, 2003 In Use
65174-0880-50 65174-0880 Sodium Iodide I 131 HICON 1000.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral April 7, 2003 In Use
23155-0685-31 23155-0685 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
23155-0686-31 23155-0686 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
50242-0087-01 50242-0087 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
55150-0352-01 55150-0352 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
55150-0353-01 55150-0353 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
55150-0354-01 55150-0354 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
68682-0002-60 68682-0002 Bexarotene Bexarotene 1.0 g/100g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical June 28, 2000 In Use
69448-0014-63 69448-0014 LEUPROLIDE CAMCEVI 42.0 mg/.37g Hormonal Therapy GnRH Agonist Subcutaneous April 5, 2022 In Use
17478-0547-01 17478-0547 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 In Use

Found 10,000 results in 4 milliseconds — Export these results